ClinicalTrials.gg
CompletedNCT00124943SNAPIST-IIIUpdated Apr 2, 2012Results posted

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

A Phase 1/2 interventional study of Nanoparticle Paclitaxel in Coronary Restenosis, sponsored by Celgene Corporation. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-02.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following angioplasty for in-stent restenosis.

Read the detailed description

This study consisted of a Phase I non-randomized dose escalation phase to determine the maximum tolerated dose and a randomized Phase II component to assess preliminary efficacy. Nanoparticle paclitaxel was administered by intracoronary catheter following either successful and uncomplicated stenting of de novo lesions in native coronary arteries or following successful and uncomplicated balloon angioplasty of instent restenosis (ISR) lesions.

02

Conditions studied

  • Coronary Restenosis

Browse trials for

Keywords

  • Prevention of Instent Restenosis
03

In context

Coronary Restenosis

107 studies on the registry are indexed under Coronary Restenosis; 10 are open to participants now.

This study's enrollment of 112 is below the median of 242 across 69 interventional studies indexed under Coronary Restenosis.

Browse Coronary Restenosis studies →

Lead sponsor

Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.

First submitted before Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant and non-lactating female, and ≥ 18 years of age.
  • Diagnosis of angina pectoris or unstable angina pectoris or patients with documented silent ischemia.
  • ≥30%
  • Patient has undergone successful and uncomplicated stenting of up to 2 de novo lesions in native coronary arteries OR patient has undergone successful and uncomplicated balloon angioplasty of up to 2 in-stent restenosis (ISR) lesions in native coronary arteries, but not both.
  • Thrombolysis In Myocardial Infarction (TIMI) 3 coronary flow post-stenting for de novo lesions or post balloon angioplasty for ISR lesions.
  • No angiographic evidence of thrombus post-procedure.
  • Target vessel ≥2.5 mm diameter (by angiography).
  • Each de novo lesion is such that it is stented with ≤ 25 mm of single continuous stent.
  • Each in-stent restenosis (ISR) lesion is ≤ 25 mm in length.
  • There is at least 5 mm of non-diseased vessel on either side of target lesion(s).
  • By intravascular ultrasound (IVUS), stent is fully opposed and has a minimum diameter of 2.5 mm or an in-stent luminal area ≥ 5.0 mm\^2
  • Patient or guardian has provided a signed written to participate in the study and in all follow-up assessments using a form that is approved by the local Institutional Review Board (IRB)/Ethics Committee of the investigative site.

Exclusion criteria

Exclusion Criteria:

  • Target de novo lesion was treated with a drug-eluting stent
  • Target ISR lesion requires any treatment other than balloon angioplasty
  • Patient has both a de novo lesion and an ISR lesion.
  • If more than 2 lesions are treated with percutaneous coronary intervention (PCI), or it is anticipated that additional lesions will require treatment within 2 months.
  • Previous PCI within preceding two months.
  • Intended surgical intervention within 6 months of enrollment in the study.
  • Unprotected left main disease with >50% stenosis
  • Malapposition, dissection, or unmasking of a significant narrowing in the inflow or outflow area of the implanted stent.
  • Women who are pregnant and women of child bearing potential who do not use adequate
  • Previous participation in another study with any drug or device within the past 30 days or current enrollment in any other clinical protocol or investigational drug or device trial.
  • Patient has a of less than 12 months or there are factors making clinical and/or angiographic follow-up difficult
  • Any significant medical condition which, in the investigator's opinion, may interfere with the patient's optimal participation in the study
  • Heart transplant candidate or recipient
  • Patient is or is positive.
  • Patient has experienced a Q wave or a non Q wave myocardial infarction (MI) with documented total creatine kinase (CK) ≥2 times normal within the preceding 24 hours and the CK and creatine kinase-MB fraction (CK-MB) enzymes remain above normal at the time of the procedure.
  • Cardiogenic shock: sustained systolic blood pressure (SBP) less than 80 mmHg, with no response to fluids or SBP less than 100 mmHg with vasopressors (in absence of bradycardia)
  • Any individual who may refuse a blood transfusion
  • Documented major gastro-intestinal bleeding within 3 months
  • The following lab values at baseline are exclusionary:

    • Serum creatinine > 2.5 mg/dl;
    • count \< 150,000 cells/mm\^3;
    • (ANC) \< 2000 cells/mm\^3;
    • (HGB) \<9 g/dl;
    • Total >1.5 mg/dl;
    • (SGPT) > 2.5 x (ULN);
    • Aspartate Aminotransferase (SGOT) > 2.5 x ULN;
    • Alkaline phosphatase > 2.5 x ULN.
  • Known allergy// to the study drug; to any taxanes; or to any required study treatment: aspirin, clopidogrel bisulfate, stent materials
  • Pre-existing peripheral neuropathy of National Cancer Institute (NCI) Toxicity Grade > 1.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    10 mg/m^2 nanoparticle paclitaxel

    Participants received a single dose of 10 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesion) or balloon angioplasty (in-stent restenosis lesions).

    Drug: Nanoparticle Paclitaxel

  • Experimental
    22 mg/m^2 nanoparticle paclitaxel

    Participants received a single dose of 22 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).

    Drug: Nanoparticle Paclitaxel

  • Experimental
    35 mg/m^2 nanoparticle paclitaxel

    Participants received a single dose of 35 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).

    Drug: Nanoparticle Paclitaxel

  • Experimental
    45 mg/m^2 nanoparticle paclitaxel

    Participants received a single dose of 45 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).

    Drug: Nanoparticle Paclitaxel

Interventions

  • Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.

    Also known as: ABI-007, Abraxane®, Coroxane™

06

What researchers measure

Primary outcomes

  1. Phase I: Number of Participants With Dose-limiting Toxicities

    Toxicities were evaluated based on the U.S. National Cancer Institute (NCI) Common Terminology Criteria (CTC) for Adverse Events version 3.0. Any drug-related toxicities considered CTC Grade 3 or 4 were considered dose limiting. The maximum tolerated dose was defined as the lesser of 45 mg/m\^2 or the dose at which any drug related toxicities were observed.

    Time frame: Up to 1 week following percutaneous coronary intervention.

  2. Number of Participants With Procedural Complications

    Procedural complications include the following: 1. Haemodynamic monitoring: changes in heart rate, arterial blood pressure or electrocardiogram changes; 2. Arrhythmia: premature ventricular complexes, brady or tachyarrhythmia; 3. Allergic reactions: rash, flushing, pyrexia, urticaria, angio-oedema; 4. Angiographic complications: coronary artery spasm, dissection, thrombosis, TIMI (Thrombolysis In Myocardial Infarction) flow, no reflow; 5. Clinical changes: chest pain.

    Time frame: From Day 0 - Day 1 (from study drug administration until 24 hours post-procedure).

  3. Number of Participants With Treatment Emergent Adverse Events (AEs)

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. An SAE is any event that: * is fatal or life threatening * results in persistent or significant disability or or incapacity; * requires or prolongs existing hospitalization; * is a congenital anomaly/birth defect in the offspring of a patient who received medication; * conditions not included above that may jeopardize the patient or require intervention to prevent one of the outcomes listed above.

    Time frame: Up to 6 months.

  4. Number of Participants With Major Adverse Cardiac Events (MACE) at 1 Month

    Major Adverse Cardiac Events (MACE) includes cardiac death, Coronary Artery Bypass Surgery, Myocardial Infarction, Target Vessel Revascularization (TVR) or Target Lesion Revascularization (TLR) and stent/vessel thrombotic occlusion.

    Time frame: From the day of Percutaneous Coronary Intervention to 1 Month.

  5. Number of Participants With Major Adverse Cardiac Events (MACE) at 6 Months

    Major Adverse Cardiac Events (MACE) includes cardiac death, Coronary Artery Bypass Surgery, Myocardial Infarction, Target Vessel Revascularization (TVR) or Target Lesion Revascularization (TLR) and stent/vessel thrombotic occlusion.

    Time frame: From the day of Percutaneous Coronary Intervention to Month 6.

Secondary outcomes

  1. Percentage of Participants With Binary Restenosis

    Binary restenosis was assessed by quantitative coronary angiography and defined as \>50% diameter stenosis within the stented region (In-stent) or the stented region plus 5 mm on either side of the stent (In-segment) at follow-up. Angiograms were centrally assessed by the Angiographic Core Laboratory.

    Time frame: 6 months

  2. Late Lumen Loss

    Late lumen loss represents the extent of neointimal hyperplasia within the stented region (In-stent) or the stented region plus 5 mm on either side of the stent (In-segment) and was measured by quantitative coronary angiography. Late Loss = Minimum Lumen Diameter (MLD) Post Procedure minus the MLD at Follow-up.

    Time frame: Day 0 (post-procedure baseline) and 6 months.

  3. Percentage of In-Stent Volume Obstruction at 6 Months

    In-stent volume obstruction at 6 months was measured by intra-vascular ultrasound (IVUS) and centrally assessed by the IVUS Core Laboratory. Percent in-stent volume obstruction was calculated as neointimal volume / stent volume \* 100.

    Time frame: 6 months

07

Results

Posted Mar 8, 2012

Participant flow

Phase I
Participant flow — Phase I
Milestone10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Started3333
Completed3333
Not completed0000
Phase II
Participant flow — Phase II
Milestone10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Started351355
Completed349350
Not completed0205
Withdrew: Adverse event0201
Withdrew: Protocol violation0001
Withdrew: Lost to follow-up0001
Withdrew: Withdrawal by subject0002

Outcome measures

PrimaryPhase I: Number of Participants With Dose-limiting Toxicities

Toxicities were evaluated based on the U.S. National Cancer Institute (NCI) Common Terminology Criteria (CTC) for Adverse Events version 3.0. Any drug-related toxicities considered CTC Grade 3 or 4 were considered dose limiting. The maximum tolerated dose was defined as the lesser of 45 mg/m\^2 or the dose at which any drug related toxicities were observed.

Time frame:
Up to 1 week following percutaneous coronary intervention.
Reported as:
Number · participants
Phase I: Number of Participants With Dose-limiting Toxicities
participants10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Phase I: Number of Participants With Dose-limiting Toxicities0000
PrimaryNumber of Participants With Procedural Complications

Procedural complications include the following: 1. Haemodynamic monitoring: changes in heart rate, arterial blood pressure or electrocardiogram changes; 2. Arrhythmia: premature ventricular complexes, brady or tachyarrhythmia; 3. Allergic reactions: rash, flushing, pyrexia, urticaria, angio-oedema; 4. Angiographic complications: coronary artery spasm, dissection, thrombosis, TIMI (Thrombolysis In Myocardial Infarction) flow, no reflow; 5. Clinical changes: chest pain.

Time frame:
From Day 0 - Day 1 (from study drug administration until 24 hours post-procedure).
Reported as:
Number · participants
Number of Participants With Procedural Complications
participants10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Number of Participants With Procedural Complications1519
Statistical analysis
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · Fisher Exact · p = 0.396
PrimaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. An SAE is any event that: * is fatal or life threatening * results in persistent or significant disability or or incapacity; * requires or prolongs existing hospitalization; * is a congenital anomaly/birth defect in the offspring of a patient who received medication; * conditions not included above that may jeopardize the patient or require intervention to prevent one of the outcomes listed above.

Time frame:
Up to 6 months.
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
participants10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Patients with at Least 1 AE343348
Patients with at Least 1 Serious AE014018
Statistical analysis
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · Fisher Exact · p = 0.783
SecondaryPercentage of Participants With Binary Restenosis

Binary restenosis was assessed by quantitative coronary angiography and defined as \>50% diameter stenosis within the stented region (In-stent) or the stented region plus 5 mm on either side of the stent (In-segment) at follow-up. Angiograms were centrally assessed by the Angiographic Core Laboratory.

Time frame:
6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Binary Restenosis
percentage of participants10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
In-stent0.025.50.034.5
In-segment0.027.50.034.5
Statistical analysis
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · Fisher Exact · p = 0.293
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · Fisher Exact · p = 0.400
PrimaryNumber of Participants With Major Adverse Cardiac Events (MACE) at 1 Month

Major Adverse Cardiac Events (MACE) includes cardiac death, Coronary Artery Bypass Surgery, Myocardial Infarction, Target Vessel Revascularization (TVR) or Target Lesion Revascularization (TLR) and stent/vessel thrombotic occlusion.

Time frame:
From the day of Percutaneous Coronary Intervention to 1 Month.
Reported as:
Number · participants
Number of Participants With Major Adverse Cardiac Events (MACE) at 1 Month
participants10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Number of Participants With Major Adverse Cardiac Events (MACE) at 1 Month0101
Statistical analysis
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · Fisher Exact · p = >0.999
PrimaryNumber of Participants With Major Adverse Cardiac Events (MACE) at 6 Months

Major Adverse Cardiac Events (MACE) includes cardiac death, Coronary Artery Bypass Surgery, Myocardial Infarction, Target Vessel Revascularization (TVR) or Target Lesion Revascularization (TLR) and stent/vessel thrombotic occlusion.

Time frame:
From the day of Percutaneous Coronary Intervention to Month 6.
Reported as:
Number · participants
Number of Participants With Major Adverse Cardiac Events (MACE) at 6 Months
participants10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Number of Participants With Major Adverse Cardiac Events (MACE) at 6 Months07016
Statistical analysis
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · Fisher Exact · p = 0.061
SecondaryLate Lumen Loss

Late lumen loss represents the extent of neointimal hyperplasia within the stented region (In-stent) or the stented region plus 5 mm on either side of the stent (In-segment) and was measured by quantitative coronary angiography. Late Loss = Minimum Lumen Diameter (MLD) Post Procedure minus the MLD at Follow-up.

Time frame:
Day 0 (post-procedure baseline) and 6 months.
Reported as:
Mean · mm
Late Lumen Loss
mm10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
In-stent [n=3, 46, 3, 50]0.403 ± 0.22670.871 ± 0.41880.747 ± 0.16260.835 ± 0.5328
In-segment [n=3, 47, 3, 50]0.281 ± 0.21160.631 ± 0.40700.355 ± 0.31010.697 ± 0.5323
Statistical analysis
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · Fisher Exact · p = 0.709
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · Fisher Exact · p = 0.495
SecondaryPercentage of In-Stent Volume Obstruction at 6 Months

In-stent volume obstruction at 6 months was measured by intra-vascular ultrasound (IVUS) and centrally assessed by the IVUS Core Laboratory. Percent in-stent volume obstruction was calculated as neointimal volume / stent volume \* 100.

Time frame:
6 months
Reported as:
Mean · Percentage of obstruction
Percentage of In-Stent Volume Obstruction at 6 Months
Percentage of obstruction10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Percentage of In-Stent Volume Obstruction at 6 Months14.080 ± 11.516324.908 ± 15.322031.016 ± 8.972221.663 ± 14.0249
Statistical analysis
  • 22 mg/m^2 Nanoparticle Paclitaxel vs 45 mg/m^2 Nanoparticle Paclitaxel · ANOVA · p = 0.317P-value testing dose group differences based on an analysis of variance with dose effect in the model.

Adverse events

Collected over Up to 6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 mg/m^2 Nanoparticle Paclitaxel—0/3 (0%)3/3 (100%)
22 mg/m^2 Nanoparticle Paclitaxel—14/51 (27.5%)34/51 (66.7%)
35 mg/m^2 Nanoparticle Paclitaxel—0/3 (0%)3/3 (100%)
45 mg/m^2 Nanoparticle Paclitaxel—18/55 (32.7%)31/55 (56.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
Event10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
In-stent coronary artery restenosisInjury, poisoning and procedural complications0/34/510/38/55
Coronary artery restenosisInjury, poisoning and procedural complications0/33/510/37/55
Thoracic vertebral fractureInjury, poisoning and procedural complications0/31/510/30/55
Myocardial infarctionCardiac disorders0/31/510/31/55
Angina pectorisCardiac disorders0/31/510/30/55
Chest painGeneral disorders0/31/510/31/55
Chest discomfortGeneral disorders0/31/510/30/55
Arterial disorderVascular disorders0/31/510/30/55
HypertensionVascular disorders0/31/510/30/55
Abdominal painGastrointestinal disorders0/31/510/30/55
Most frequent other events
Showing 10 of 34
Most frequent other events
Event10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle Paclitaxel
Aspartate aminotransferase increasedInvestigations2/34/511/33/55
Blood creatine phosphokinase MB increasedInvestigations2/34/510/33/55
Troponin T increasedInvestigations2/31/510/31/55
DizzinessNervous system disorders2/30/510/32/55
Blood creatine phosphokinase increasedInvestigations1/30/510/31/55
Electrocardiogram ST-T changeInvestigations1/30/510/30/55
White blood cell count decreasedInvestigations1/31/510/31/55
Alanine aminotransferase increasedInvestigations0/34/511/32/55
Troponin increasedInvestigations0/32/511/31/55
Chest discomfortGeneral disorders1/31/510/30/55

Baseline characteristics

Age Continuous
Age Continuous(years)10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle PaclitaxelTotal
Mean63.7 ± 6.5159.0 ± 9.2663.3 ± 6.8160.3 ± 8.8959.9 ± 8.94
Sex: Female, Male
Sex: Female, Male(Participants)10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle PaclitaxelTotal
Female12011537
Male23124075
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle PaclitaxelTotal
Black, of African Heritage01034
White, Non-Hispanic and Non-Latino34434696
White, Hispanic or Latino060612
Weight
Weight(kg)10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle PaclitaxelTotal
Mean82.80 ± 10.31883.56 ± 13.65991.33 ± 21.33385.01 ± 17.91584.46 ± 15.880
Lesion type
Lesion type(participants)10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle PaclitaxelTotal
Patients with de novo Lesions349350105
Patients with In-Stent Restenosis Lesions02057
Diabetes mellitis
Diabetes mellitis(participants)10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle PaclitaxelTotal
No Diabetes34024691
Insulin Dependent05016
Non-Insulin Dependent061815
Minimum Lumen Diameter
Minimum Lumen Diameter(mm)10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle PaclitaxelTotal
Mean0.790 ± 0.39410.842 ± 0.36280.762 ± 0.18040.986 ± 0.37400.908 ± 0.3691
Reference Diameter
Reference Diameter(mm)10 mg/m^2 Nanoparticle Paclitaxel22 mg/m^2 Nanoparticle Paclitaxel35 mg/m^2 Nanoparticle Paclitaxel45 mg/m^2 Nanoparticle PaclitaxelTotal
Mean2.668 ± 0.07532.577 ± 0.38992.650 ± 0.42902.703 ± 0.46642.643 ± 0.4259

2 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2005
First posted
Jul 29, 2005
Start
Jul 2005
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Mar 8, 2012
Last update
Apr 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00124943
Responsible party
Sponsor
First posted
Jul 29, 2005
Start date
Jul 2005
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Mar 8, 2012
Last update
Apr 2, 2012

Study contacts

Jose' Iglesias, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion